Teva Pharmaceutical enter permit option agreement for OpRegen product BioTime.

West, Chief Executive Officer at BioTime. That is consistent with our focus on making Cell Treat, our majority owned subsidiary, a middle for developing cell structured therapies for retinal and neural degenerative diseases. Ophir Shahaf, CEO of HBL added: We are content and proud to start to see the company, that was established on the basis of technology created at Hadassah Medical Company, develop and grow to the stage where it could aggressively advance its lead product into the clinic, with the support of the ultimate partners in the field. .. Cell Remedy, Teva Pharmaceutical enter permit option agreement for OpRegen product BioTime, Inc. , Cell Treatment Neurosciences Ltd., and Hadasit Bio-Holdings Ltd.Co-authors are Babak Ardekani, Ph.D., Shree Bhaskar, M.D., Tana Clarke, B.S., and Joseph Rhinewine, M.A. . The extensive research was sponsored by an NIMH grant.

Better Sex Through Outercourse: Expanding Sexual Horizons Even those individuals who consistently enjoy very good sex wouldn’t brain having better still sex – and that is where a little focus on outercourse will come in handy. Although incorporating even more outercourse into one’s sex lifestyle may take a small practice, the total benefits can be really worth it. And since a content sex life generally boosts a man’s penis health, it’s rather a ‘win’ all around. What is outercourse? The term outercourse identifies sexual activity which will not involve penetration of either the vagina or the anus.